SAFETY DATA SHEET

Ertugliflozin / Metformin Formulation

SECTION 1. IDENTIFICATION

Product name : Ertugliflozin / Metformin Formulation
Other means of identification : No data available

Manufacturer or supplier’s details
Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTeward@merck.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations
Acute toxicity (Oral) : Category 4

GHS label elements
Hazard pictograms : !

Signal Word : Warning
Hazard Statements : H302 Harmful if swallowed.
Precautionary Statements : Prevention:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Response:
P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel unwell. Rinse mouth.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.
SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Common Name/Synonym</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin hydrochloride</td>
<td>No data available</td>
<td>1115-70-4</td>
<td>&gt;= 60 - &lt; 80 *</td>
</tr>
<tr>
<td>Cellulose</td>
<td>No data available</td>
<td>9004-34-6</td>
<td>&gt;= 10 - &lt; 30 *</td>
</tr>
<tr>
<td>Magnesium stearate-Octadecanoic acid, magnesium salt (2:1)</td>
<td>557-04-0</td>
<td></td>
<td>&gt;= 1 - &lt; 5 *</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>No data available</td>
<td>1210344-83-4</td>
<td>&gt;= 0.1 - &lt; 1 *</td>
</tr>
</tbody>
</table>

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap. Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. Harmful if swallowed.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during fire: Avoid generating dust; fine dust dispersed in air in sufficient
fighting concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Nitrogen oxides (NOx)
- Metal oxides

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for fire-fighters:
In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
Use only with adequate ventilation.

Advice on safe handling:
Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>metformin hydrochloride</td>
<td>1115-70-4</td>
<td>TWA</td>
<td>1 mg/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Total dust)</td>
<td>10 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (respirable dust fraction)</td>
<td>3 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWAEV (total dust)</td>
<td>10 mg/m³</td>
<td>CA QC OEL</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWAEV</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable)</td>
<td>10 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable)</td>
<td>3 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>1210344-83-4</td>
<td>TWA</td>
<td>10 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

**Engineering measures:** All engineering controls should be implemented by facility design and operated in accordance with GMP principles to
protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

**Personal protective equipment**

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection: Chemical-resistant gloves

Remarks: Consider double gloving.

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance: powder

Color: No data available

Odor: No data available

Odor Threshold: No data available

pH: No data available

Melting point/freezing point: No data available

Initial boiling point and boiling: No data available
SAFETY DATA SHEET

Ertugliflozin / Metformin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.0</td>
<td>04/04/2023</td>
<td>590547-00018</td>
<td>10/01/2022</td>
<td>04/01/2016</td>
</tr>
</tbody>
</table>

range

Flash point : Not applicable
Evaporation rate : Not applicable
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapor pressure : Not applicable
Relative vapor density : Not applicable
Relative density : No data available
Density : No data available
Solubility(ies)
  Water solubility : No data available
Partition coefficient: n-octanol/water : Not applicable
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, kinematic : Not applicable
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions
  May form explosive dust-air mixture during processing, handling or other means.
  Can react with strong oxidizing agents.
Conditions to avoid
  Heat, flames and sparks.
  Avoid dust formation.
SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Harmful if swallowed.

Product:
Acute oral toxicity: Acute toxicity estimate: 1,337 mg/kg
Method: Calculation method

Components:

metformin hydrochloride:
Acute oral toxicity: LD50 (Rat): 1,000 mg/kg
LD50 (Mouse): 1,450 - 3,500 mg/kg
LD50 (Monkey): 463 mg/kg
LD50 (Rabbit): 350 mg/kg
LD50 (Guinea pig): 500 mg/kg

Cellulose:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg

Magnesium stearate:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials
Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Ertugliflozin:
SAFETY DATA SHEET

Ertugliflozin / Metformin Formulation

Version 5.0  Revision Date: 04/04/2023  SDS Number: 590547-00018  Date of last issue: 10/01/2022  Date of first issue: 04/01/2016

Acute oral toxicity: LD50 (Rat): 500 mg/kg
Acute inhalation toxicity: Remarks: No data available
Acute dermal toxicity: Remarks: No data available

Skin corrosion/irritation
Not classified based on available information.

Components:
metformin hydrochloride:
Species: Rabbit
Result: Mild skin irritation
Magnesium stearate:
Species: Rabbit
Result: No skin irritation
Remarks: Based on data from similar materials
Ertugliflozin:
Result: Corrosive

Serious eye damage/eye irritation
Not classified based on available information.

Components:
metformin hydrochloride:
Species: Rabbit
Result: Mild eye irritation
Magnesium stearate:
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials
Ertugliflozin:
Result: Severe irritation

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.
Respiratory sensitization
Not classified based on available information.
Components:

Magnesium stearate:
- **Test Type**: Maximization Test
- **Routes of exposure**: Skin contact
- **Species**: Guinea pig
- **Method**: OECD Test Guideline 406
- **Result**: negative
- **Remarks**: Based on data from similar materials

Ertugliflozin:
- **Test Type**: Local lymph node assay (LLNA)
- **Result**: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

**metformin hydrochloride**:
- **Genotoxicity in vitro**
  - **Test Type**: Bacterial reverse mutation assay (AMES)
    - **Result**: negative
  - **Test Type**: in vitro test
    - **Test system**: mouse lymphoma cells
    - **Result**: negative
  - **Test Type**: Chromosomal aberration
    - **Test system**: Human lymphocytes
    - **Result**: negative
- **Genotoxicity in vivo**
  - **Test Type**: Micronucleus test
    - **Species**: Mouse
    - **Application Route**: Oral
    - **Result**: negative

**Cellulose**:
- **Genotoxicity in vitro**
  - **Test Type**: Bacterial reverse mutation assay (AMES)
    - **Result**: negative
  - **Test Type**: In vitro mammalian cell gene mutation test
    - **Result**: negative
- **Genotoxicity in vivo**
  - **Test Type**: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
    - **Species**: Mouse
    - **Application Route**: Ingestion
    - **Result**: negative

**Magnesium stearate**:
- **Genotoxicity in vitro**
  - **Test Type**: In vitro mammalian cell gene mutation test
    - **Result**: negative
Ertugliflozin:

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Rat
  - Result: negative

Carcinogenicity:
Not classified based on available information.

Components:

metformin hydrochloride:
- Species: Mouse
  - Exposure time: 91 weeks
  - Dose: 1500 mg/kg body weight
  - Result: negative

- Species: Rat, male
  - Application Route: Oral
  - Exposure time: 104 weeks
  - Dose: 900 mg/kg body weight
  - Result: negative

- Species: Rat, female
  - Application Route: Oral
  - Exposure time: 104 weeks
  - LOAEL: 900 mg/kg body weight
  - Result: negative
  - Target Organs: Uterus (including cervix)
  - Remarks: The mechanism or mode of action may not be relevant in humans.

Cellulose:
- Species: Rat
  - Application Route: Ingestion
  - Exposure time: 72 weeks

Remarks:
Based on data from similar materials
Result: negative

Ertugliflozin:
Species: Mouse
Application Route: Oral
Exposure time: 2 Years
Result: negative

Species: Rat
Application Route: Oral
Exposure time: 2 Years
Result: negative

Carcinogenicity - Assessment: Weight of evidence does not support classification as a carcinogen

Reproductive toxicity
Not classified based on available information.

Components:

metformin hydrochloride:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 600 mg/kg body weight
Result: No effects on fertility.

Effects on fetal development: Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 600 mg/kg body weight
Result: No teratogenic effects.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Embryo-fetal toxicity: NOAEL: 140 mg/kg body weight
Result: No teratogenic effects.

Cellulose:
Effects on fertility: Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Magnesium stearate:
Ertugliflozin / Metformin Formulation

Effects on fertility:
- Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
- Species: Rat
- Application Route: Ingestion
- Method: OECD Test Guideline 422
- Result: negative
- Remarks: Based on data from similar materials

Effects on fetal development:
- Test Type: Embryo-fetal development
- Species: Rat
- Application Route: Ingestion
- Result: negative
- Remarks: Based on data from similar materials

Ertugliflozin:

Effects on fertility:
- Test Type: Fertility/early embryonic development
- Species: Rat
- Application Route: Oral
- Fertility: NOAEL: 250 mg/kg body weight
- Remarks: Maternal toxicity observed. No significant adverse effects were reported

- Test Type: Fertility/early embryonic development
  Species: Rabbit
  Application Route: Oral
  Fertility: NOAEL: 200 mg/kg body weight
  Remarks: No significant adverse effects were reported

Effects on fetal development:
- Test Type: Embryo-fetal development
  Species: Rat
  Application Route: Oral
  Developmental Toxicity: NOAEL: 50 mg/kg body weight
  Remarks: Adverse developmental effects were observed

- Test Type: Embryo-fetal development
  Species: Rabbit
  Application Route: Oral
  Developmental Toxicity: NOAEL: 250 mg/kg body weight
  Remarks: No significant adverse effects were reported

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Not classified based on available information.

Components:

Ertugliflozin:
- Routes of exposure: Oral
- Target Organs: Kidney, Stomach, Prostate
- Assessment: May cause damage to organs through prolonged or repeated exposure.
### Repeated dose toxicity

#### Components:

**metformin hydrochloride:**

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>125 mg/kg</td>
<td>Oral</td>
<td>1 year</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit</td>
<td>100 mg/kg</td>
<td>Oral</td>
<td>1 Year</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dog</td>
<td>50 mg/kg</td>
<td>Subcutaneous</td>
<td>2 year</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

**Cellulose:**

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>&gt;= 9,000 mg/kg</td>
<td>Ingestion</td>
<td>90 Days</td>
</tr>
</tbody>
</table>

**Magnesium stearate:**

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>&gt; 100 mg/kg</td>
<td>Ingestion</td>
<td>90 Days</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

**Ertugliflozin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>500 mg/kg</td>
<td>Oral</td>
<td>30 d</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>250 mg/kg</td>
<td>Oral</td>
<td>30 d</td>
<td>Kidney, Bone, Stomach</td>
</tr>
</tbody>
</table>
Species: Rat
LOAEL: 25 mg/kg
Exposure time: 90 d
Target Organs: Kidney, Gastrointestinal tract, Prostate

Species: Dog
NOAEL: 150 mg/kg
Application Route: Oral
Exposure time: 270 d
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 90 d
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 28 d
Target Organs: Bone
Remarks: No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

metformin hydrochloride:

Skin contact: Remarks: May irritate skin.
Eye contact: Remarks: May irritate eyes.
Ingestion: Symptoms: Diarrhea, Nausea, Vomiting, Gastrointestinal discomfort, flatulence, asthenia, Fatigue, Headache

Ertugliflozin:

Ingestion: Symptoms: The most common side effects are: Headache, constipation, Diarrhea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

metformin hydrochloride:

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity)
NOEC (Pimephales promelas (fathead minnow)): 10 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)
NOEC (Daphnia magna (Water flea)): 40 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms
EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Cellulose:
Toxicity to fish
LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Magnesium stearate:
Toxicity to fish
LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates
EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants
EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms
EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
**Ertugliflozin / Metformin Formulation**

**Remarks:** Based on data from similar materials

**Ertugliflozin:**

**Toxicity to algae/aquatic plants:**

- **EC50** (Pseudokirchneriella subcapitata (green algae)): 77 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

- **NOEC** (Pseudokirchneriella subcapitata (green algae)): 50 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

**Toxicity to fish (Chronic toxicity):**

- **NOEC** (Pimephales promelas (fathead minnow)): 1 mg/l
  - Exposure time: 32 d
  - Method: OECD Test Guideline 210
  - Remarks: No toxicity at the limit of solubility.

**Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):**

- **NOEC** (Daphnia magna (Water flea)): 2.14 mg/l
  - Exposure time: 21 d
  - Method: OECD Test Guideline 211
  - Remarks: No toxicity at the limit of solubility.

**Toxicity to microorganisms:**

- **EC50**: > 1,000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209

- **NOEC**: 1,000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209

**Persistence and degradability**

**Components:**

**Metformin hydrochloride:**

- Biodegradability: Result: rapidly degradable
  - Biodegradation: 50%
  - Exposure time: 2 hrs

**Cellulose:**

- Biodegradability: Result: Readily biodegradable.

**Magnesium stearate:**

- Biodegradability: Result: Not biodegradable
  - Remarks: Based on data from similar materials

**Ertugliflozin:**

- Biodegradability: Result: Not readily biodegradable.
  - Biodegradation: 40.8%
  - Exposure time: 28 d
Bioaccumulative potential

Components:

- **metformin hydrochloride:**
  - Partition coefficient: n-octanol/water: log Pow: -2

- **Magnesium stearate:**
  - Partition coefficient: n-octanol/water: log Pow: > 4

- **Ertugliflozin:**
  - Partition coefficient: n-octanol/water: log Pow: 2.47

Mobility in soil

Components:

- **metformin hydrochloride:**
  - Distribution among environmental compartments: log Koc: 4.3
    Method: OECD Test Guideline 106

- **Ertugliflozin:**
  - Distribution among environmental compartments: log Koc: 2.88

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

- **Waste from residues:**
  Dispose of in accordance with local regulations.

- **Contaminated packaging:**
  Empty containers should be taken to an approved waste handling site for recycling or disposal.
  If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

**UNRTDG**
Not regulated as a dangerous good

**IATA-DGR**
Not regulated as a dangerous good

**IMDG-Code**
Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
Not applicable for product as supplied.
SAFETY DATA SHEET

Ertugliflozin / Metformin Formulation

Domestic regulation

TDG
Not regulated as a dangerous good

Special precautions for user
Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
CA BC OEL : Canada. British Columbia OEL
CA QC OEL : Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA : 8-hour, time-weighted average
CA AB OEL / TWA : 8-hour Occupational exposure limit
CA BC OEL / TWA : 8-hour time weighted average
CA QC OEL / TWA / TWAEV : Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemicals in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardisation; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Develop-
SAFETY DATA SHEET

Ertugliflozin / Metformin Formulation

Version 5.0  Revision Date: 04/04/2023  SDS Number: 590547-00018  Date of last issue: 10/01/2022
Date of first issue: 04/01/2016

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 04/04/2023
Date format: mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CA / Z8